Verona pharma to present additional analyses of positive phase 3 enhance studies in copd at chest 2023

Pdufa target action date of june 26, 2024 pooled analysis and subgroup data further support potential of ensifentrine,  an investigational, novel, selective, dual inhibitor of pde3 and pde4 london and raleigh, n.c., oct. 03, 2023 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), announces four presentations on additional analyses from its successful phase 3 enhance studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“copd”) will be presented at chest annual meeting (“chest”) 2023.
VRNA Ratings Summary
VRNA Quant Ranking